US FDA approves amisulpride injection for the prevention and treatment of post-operative nausea and vomiting (PONV)

The approval of this IV formulation of amisulpride, supported by data from four Phase III studies, covers treatment of PONV in adults who received no antiemetic prophylaxis or one from another class, and prevention (alone or in combination with an antiemetic of a different class)


Biospace Inc.